FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Pamlico Capital II, L.P. 		2. Issuer Name and Ticker or Trading Symbol

GREENWAY MEDICAL TECHNOLOGIES INC [ GWAY ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

150 NORTH COLLEGE STREET, SUITE 2400 		3. Date of Earliest Transaction (MM/DD/YYYY)

11/4/2013
(Street)

CHARLOTTE, NC 28202
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   11/4/2013     U    5284679   D $20.35   0   I   See footnotes   (1) (2)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $6.92   11/4/2013     U         10000      (3) 10/18/2020   Common Stock   10000   $13.43   0   D    

Explanation of Responses:
( 1)  The sole general partner of Pamlico Capital II, L.P. is Pamlico Capital GP II LLC (together with Pamlico Capital II, L.P., the "Reporting Persons"). The managing members of Pamlico Capital GP II are Scott B. Perper, L. Watts Hamrick, III and Frederick W. Eubank, II and all matters relating to the voting or disposition of the shares beneficially owned by Pamlico Capital II, L.P. require the approval of a majority of such managing members. Scott B. Perper, L. Watts Hamrick, III and Frederick W. Eubank, II each disclaim beneficial ownership of the shares beneficially owned by Pamlico Capital II, L.P.
( 2)  Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.
( 3)  This option was granted to D. Neal Morrison, a director of the Issuer and member of the Reporting Person. Pursuant to certain legal agreements with the Reporting Person, Mr. Morrison is deemed to hold the option for the benefit of the Reporting Person and its affiliates and may exercise the option only upon the direction of the Reporting Person. This option, which is fully vested, was canceled in the merger in exchange for a cash payment of $134,300, representing the difference between the exercise price of the option and $20.35 per share of the underlying Greenway Medical Technologies, Inc. common stock.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Pamlico Capital II, L.P.
150 NORTH COLLEGE STREET
SUITE 2400
CHARLOTTE, NC 28202
X

Pamlico Capital GP II LLC
150 NORTH COLLEGE STREET
SUITE 2400
CHARLOTTE, NC 28202
X


Signatures
Pamlico Capital II, L.P., /s/ Kristy Burleigh 11/5/2013
** Signature of Reporting Person Date

Pamlico Capital GP II, LLC, /s/ Watts Hamrick 11/5/2013
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Greenway Medical Technologies Com USD0.0001 (NYSE:GWAY)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Greenway Medical Technologies Com USD0.0001 Charts.
Greenway Medical Technologies Com USD0.0001 (NYSE:GWAY)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Greenway Medical Technologies Com USD0.0001 Charts.